LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

33.62 -7.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.45

Max

33.95

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.3M -123M
Pardavimai	3.7M 3.9M
Pelnas, tenkantis vienai akcijai	-1.29
Pelno marža	-3,161.261
Darbuotojai	594
EBITDA	20M -122M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+161.36% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-855M 3.6B
Ankstesnė atidarymo kaina	40.85
Ankstesnė uždarymo kaina	33.62

Naujienos nuotaikos

By Acuity

76%

24%

312 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-27 17:33; UTC

Svarbiausios naujienos

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026-03-27 17:00; UTC

Svarbiausios naujienos

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026-03-27 16:03; UTC

Svarbiausios naujienos

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026-03-27 14:50; UTC

Pagrindinės rinkos jėgos

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

2026-03-27 14:37; UTC

Įsigijimai, susijungimai, perėmimai

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

2026-03-27 14:29; UTC

Svarbiausios naujienos

EU Finance Ministers Tally Economic Hit of Iran War -- Update

2026-03-27 14:16; UTC

Svarbiausios naujienos

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

2026-03-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 19:16; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026-03-27 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026-03-27 19:04; UTC

Rinkos pokalbiai

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026-03-27 19:03; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 19:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026-03-27 18:12; UTC

Rinkos pokalbiai

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026-03-27 17:36; UTC

Svarbiausios naujienos

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026-03-27 17:34; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026-03-27 17:29; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026-03-27 16:38; UTC

Rinkos pokalbiai

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026-03-27 16:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026-03-27 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 15:43; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin Says Iran War Raising Economic Uncertainty

2026-03-27 14:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

2026-03-27 14:26; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

2026-03-27 14:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 14:14; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

161.36% į viršų

12 mėnesių prognozė

Vidutinis 88 USD 161.36%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

312 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.